Talin autoinhibition is required for normal hemostasis

Venkatesh B
University of British Columbia
September 8, 2025
Platelets
https://pubmed.ncbi.nlm.nih.gov/40916946

This article is currently being updated. View its version on PubMed.

https://pubmed.ncbi.nlm.nih.gov/40916946

Research summary

Blocking talin autoinhibition through the E1770A point mutation in Tln1 impairs platelet function. Homozygous and heterozygous Tln1^E1770A mice exhibit prolonged bleeding time, reduced platelet aggregation, and defective clot retraction. Despite intact integrin inside-out activation, these defects suggest talin autoinhibition regulates broader aspects of platelet function and hemostasis.

Key outcome of the study

Increased bleeding time, impaired clot retraction, defective platelet aggregation, no increase in integrin activation

Model

Tln1^E1770A/E1770A point mutant mouse (autoinhibition-deficient talin), C57BL/6 background

TARGET:
Tln1
Synonyms:
Talin1, TLN-1

Keywords

Hemostasis, platelet function, integrin signaling, coagulation defect models

Technical specifications

CRISPR-generated point mutation (E1770A) in Tln1, homozygous and heterozygous comparison, platelet aggregation and clot retraction assays, tail bleeding test, integrin signaling analysis

Related products

Catalogue product

No items found.

Customized product

Point mutation KI mouse

Use a point mutation mouse Knockin to circumvent complex phenotypes arising from complete Knockouts (e.g., signaling pathway problems, cross-reactivity).

Scientific excellence

From model design to experimental results
Featured in 600+ scientific articles

Collaborative approach

Collaboration with 17 Top Pharmas,
170+ Biotechs and 380+ Academic Institutions

Robust validation data on catalog models

Generated with biopharma partners and in-house

Innovative technologies

and guaranteed freedom to operate

Easy access to models

Models with certified health status from professional breeders in US and Europe